GUANGJI PHARMA.(SZ:000952) Shang Hai Zheng Quan Bao·2026-01-09 19:19Group 1 - The company held its 14th (temporary) meeting of the 11th Board of Directors on January 9, 2026, to discuss several key resolutions [1][4][61] - The board approved the repurchase and cancellation of 119,700 restricted stocks from five former employees who no longer meet the incentive conditions of the 2021 stock incentive plan [1][28][40] - The board also approved the nomination of Liu Wei as an independent director candidate, who will serve as the chair of the audit committee and a member of the remuneration and assessment committee [5][49] Group 2 - The board approved the revision and establishment of several governance systems to enhance operational standards and comply with relevant laws and regulations [8][53] - The company plans to reduce the registered capital of its wholly-owned subsidiary, Hubei Guangji Pharmaceutical Biotechnology Research Institute, by 22 million yuan, bringing the total registered capital down to 28 million yuan [55][59] - The company applied for a comprehensive credit line of 230 million yuan from Zheshang Bank, which includes a general credit limit of 130 million yuan and a low-risk credit limit of 100 million yuan [61][62] Group 3 - The company will hold its first temporary shareholders' meeting of 2026 on January 27, 2026, to discuss the approved resolutions [21][67] - The meeting will include both on-site and online voting options for shareholders [68][75] - The company ensures that all resolutions comply with the relevant laws and regulations, and the independent director candidate's qualifications will be subject to review by the Shenzhen Stock Exchange [50][71]